Doxycycline 100 mg Q12h for 12 Weeks in Hidradenitis Suppurativa
Yes, doxycycline 100 mg orally every 12 hours for 12 weeks is a recommended first-line treatment for mild-to-moderate hidradenitis suppurativa based on North American clinical guidelines. 1
Guideline-Based Recommendation
The 2019 North American Clinical Management Guidelines for HS explicitly recommend tetracyclines (including doxycycline) for mild-to-moderate HS as a 12-week course or as long-term maintenance therapy when appropriate 1. This represents a Level II recommendation (limited-quality patient-oriented evidence), making it one of the primary systemic antibiotic options for HS management.
Dosing Specifics
The standard dosing regimen is:
- 100 mg orally every 12 hours (200 mg total daily dose)
- Duration: 12 weeks as recommended by guidelines 1
- This aligns with FDA-approved dosing for severe infections requiring 100 mg Q12h 2
Supporting Evidence
Recent research validates this approach:
A 2021 prospective study of 108 HS patients treated with tetracyclines (including doxycycline 100 mg twice daily) demonstrated significant improvement in Hidradenitis Suppurativa Score (HSS), with mean reduction of 8.13 points (P < 0.0001) 3
A 2022 randomized trial showed that regular-release doxycycline 100 mg twice daily for 12 weeks achieved HiSCR (Hidradenitis Suppurativa Clinical Response) in 60% of patients, with statistically significant reductions in disease severity scores 4
Clinical Considerations
When to use this regimen:
- First-line treatment for mild-to-moderate HS (Hurley stage I-II)
- Can be used as adjunctive therapy in severe disease 1
- May be combined with other treatments (19% of patients in PIONEER 2 trial used concomitant tetracyclines with adalimumab) 1
Important caveats:
- Recurrence after cessation is frequent 1, so you may need to consider long-term maintenance therapy beyond 12 weeks
- Balance benefit against antibiotic resistance risk - duration should be individualized based on response 1
- Administer with adequate fluids to reduce esophageal irritation risk 2
- Can be given with food or milk if gastric irritation occurs 2
Predictors of better response (from recent data):
- Lower BMI
- Shorter disease duration
- Higher baseline inflammatory nodule count
- Absence of pubic/genital involvement 5
Alternative Considerations
If standard doxycycline is not tolerated or you want to minimize antibiotic resistance, modified-release doxycycline 40 mg once daily (subantimicrobial dose) has shown comparable efficacy with potentially better safety profile 4, 5, though this is not the standard guideline recommendation.
For refractory cases or more severe disease, consider escalating to clindamycin 300 mg + rifampin 300 mg twice daily as second-line therapy 1.